Kadcyla™ (ado-trastuzumab emtansine)
KADCYLA™ (ado-trastuzumab emtansine), FDA approved the product for second line treatment of HER2+ metastatic breast cancer and first line treatment for those patients who relapse within six months following adjuvant therapy.
How Kadcyla Works:
The drug, formerly known as T-DM1, is a conjugate combining the antibody trastuzumab – better known by the brand name Herceptin – and a chemotherapy drug known as DM1. The conjugate relies on the targeted nature of trastuzumab to help deliver the chemotherapeutic, DM1, to the site of the breast cancer.
KADCYLA™ (ado-trastuzumab emtansine), injection for intravenous use, as a single agent, is indicated for the treatment of patients with HER2-positive (HER2+), metastatic breast cancer (MBC) who previously received trastuzumab and a taxane, separately or in combination. Patients should have either:
- Received prior therapy for metastatic disease, or
- Developed disease recurrence during or within six months of completing adjuvant therapy